New trial tests if adding chemo to radiation boosts survival for head and neck cancer patients

NCT ID NCT07125755

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial aims to see if adding chemotherapy (cisplatin) to standard radiation therapy after surgery helps people with intermediate-risk head and neck squamous cell carcinoma live longer without the cancer returning. About 386 participants who have had surgery and show certain risk factors will be randomly assigned to receive either chemoradiotherapy or radiotherapy alone. The study is currently recruiting and will track cancer recurrence, spread, and overall survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTERMEDIATE-RISK HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SQUAMOUS CELL CANCER OF HEAD AND NECK (SCCHN)

Contacts and locations

Locations

Affiliated Hospital of Guilin Medical College
RECRUITING

Guilin, Guangxi, China
Hainan General Hospital
RECRUITING

Sanya, Hainan, China
Hunan Cancer Hospital
RECRUITING

Changsha, Hunan, China
Jiangsu Cancer Hospital
RECRUITING

Nanjing, Jiangsu, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 523000, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 523000, China
Xiangya Hospital, Central South University
RECRUITING

Changsha, Hunan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.